Скачать или смотреть Executing A Product Pivot With Vir's Mark Eisner, MD

On this week's episode of the Business of Biotech, Dr. Mark Eisner, EVP and Chief Medical Officer at Vir Biotechnology, talks about the company's post-COVID pivot into infectious diseases (Hepatitis Delta and Hepatitis B) and oncology (solid tumors), how he reprioritized the company's development candidates and assimilated Sanofi's acquired T cell engager platform, and his own transition from healthcare provider to clinical research.

This episode is brought to you by Avantor. For more information, visit avantorsciences.com

Subscribe to the podcast on your preferred platform or watch the videocast at lifescienceleader.com.

Access this and hundreds of episodes of the Business of Biotech videocast at lifescienceleader.com
---
#businessofbiotech #biopharma #biotech

Subscribe to the podcast:

Apple - https://podcasts.apple.com/us/podcast...
Spotify - https://open.spotify.com/show/5NhjpDe...
YouTube -    • The Business Of Biotech Podcast